Company Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
1.58 USD -1.25% Intraday chart for Perspective Therapeutics, Inc. +5.33% +293.03%

Business Summary

Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.

Number of employees: 118

Sales per Business

USD in Million2023Weight Delta
Precision-targeted Alpha Therapies
100.0 %
1 100.0 % -

Sales per region

USD in Million2023Weight Delta
United States
100.0 %
1 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 51 02/02/23
Director of Finance/CFO 37 -
Director of Finance/CFO 57 02/02/23
Chief Tech/Sci/R&D Officer - -
Corporate Officer/Principal - 02/04/23

Members of the board

Members of the board TitleAgeSince
Director/Board Member 58 31/05/23
Chairman 62 02/02/23
Director/Board Member 58 02/02/23
Chief Executive Officer 51 02/02/23
Director/Board Member 69 02/02/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 587,195,493 449,780,910 ( 76.60 %) 0 76.60 %

Shareholders

NameEquities%Valuation
116,773,394 19.90 % 139 M $
Commodore Capital LP
6.630 %
38,906,673 6.630 % 46 M $
Vanguard Global Advisers LLC
2.252 %
13,213,750 2.252 % 16 M $
Baker Bros. Advisors LP
1.302 %
7,639,703 1.302 % 9 M $
BlackRock Institutional Trust Co. NA
0.7734 %
4,538,389 0.7734 % 5 M $
Geode Capital Management LLC
0.4289 %
2,516,649 0.4289 % 3 M $
Alphacentric Advisors LLC
0.2994 %
1,756,756 0.2994 % 2 M $
Ghost Tree Capital LLC
0.2727 %
1,600,000 0.2727 % 2 M $
Osterweis Capital Management, Inc.
0.2696 %
1,582,100 0.2696 % 2 M $
Lori Woods
0.2672 %
1,567,814 0.2672 % 2 M $

Company contact information

Perspective Therapeutics, Inc.

2401 Elliott Avenue Suite 320

98121, Seattle

+

http://perspectivetherapeutics.com
address Perspective Therapeutics, Inc.(CATX)
  1. Stock Market
  2. Equities
  3. CATX Stock
  4. Company Perspective Therapeutics, Inc.